Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03577028 · ClinicalTrials.gov registry record · Phase 1
Study of HPN424 in Patients With Advanced Prostate Cancer
A Phase 1 study, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Terminated
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT03577028: Clinical Trial Phase 1 study, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT03577028 is a Phase 1 study that was terminated before completion, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 104 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03577028, a Phase 1 study, was terminated before completion, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
Primary Outcome
Assess safety and tolerability at increasing dose levels of HPN424 in successive cohorts of patients with metastatic castrate resistant prostate cancer (mCRPC) to estimate the maximum tolerated dose (MTD). The study was terminated early, therefore the primary goal of the final data analysis was to look at dosing schedule rather than individual dose levels. The results displayed are shown broken out by dosing schedules and no analysis of specific dose levels was performed. This analysis is as out
Interventions
- BIOLOGICAL HPN424 Fixed IV 1.3 to 150 ng/kg
- BIOLOGICAL HPN424 Prime Step IV 36 ng/kg Target
- BIOLOGICAL HPN424 1 Prime Step IV 225-300 ng/kg Target
- BIOLOGICAL HPN424 2 Prime Step IV 300 ng/kg Target
- BIOLOGICAL HPN424 2 Prime Step IV 450 ng/kg Target
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 total trials
Why NCT03577028 stopped before completion
NCT03577028 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 5 interventions - of which HPN424 Fixed IV 1.3 to 150 ng/kg is the first listed.
NCT03577028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03577028 about?
NCT03577028 is a clinical study titled "Study of HPN424 in Patients With Advanced Prostate Cancer". An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
What is the current status of trial NCT03577028?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2018-07-24. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT03577028?
The interventions under investigation include: HPN424 Fixed IV 1.3 to 150 ng/kg (BIOLOGICAL), HPN424 Prime Step IV 36 ng/kg Target (BIOLOGICAL), HPN424 1 Prime Step IV 225-300 ng/kg Target (BIOLOGICAL), HPN424 2 Prime Step IV 300 ng/kg Target (BIOLOGICAL), HPN424 2 Prime Step IV 450 ng/kg Target (BIOLOGICAL).
Who is sponsoring clinical trial NCT03577028?
This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03577028's enrollment target sits among peer trials
104 536th of 2000 higher than 1,460 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI